Glycotope Biotechnology Expands GMP Production Facility to 11 kg Antibody per Year

08-Apr-2011 - Germany

Glycotope Biotechnology GmbH has initiated the setup of further clean room facilities as a first step in the expansion of its GMP-production capacities. By mid 2011, the company will thus be able to produce 4kg of recombinant antibodies per year and up to 11 kg upon completion of works towards the end of 2011. In sum, additional 1400 m² of facility and office space will be created.

Dr. Steffen Goletz, founder and CEO of Glycotope GmbH comments: “In particular the expansion of our DSP (Downstream Processing) capacities now places us among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany”.

Other news from the department manufacturing

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Genetic mutations that lead to macular degeneration blindness mapped by new research

Genetic mutations that lead to macular degeneration blindness mapped by new research

Barroso Commission recognises contribution of biotech crops to European competitiveness

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics

Atugen AG raises EUR 5 million venture funding for siRNA therapeutics program - siRNA therapeutics patent application published

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

Organon and Schering to continue research in male fertility control separately

A human enzyme (CD 39) targets the Achilles heel of sepsis - New research suggests that CD39 significantly improves survival of mice in severe sepsis

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million

Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform